NON-SMALL CELL LUNG CANCER STAGE III
Clinical trials for NON-SMALL CELL LUNG CANCER STAGE III explained in plain language.
Never miss a new study
Get alerted when new NON-SMALL CELL LUNG CANCER STAGE III trials appear
Sign up with your email to follow new studies for NON-SMALL CELL LUNG CANCER STAGE III, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New pill may keep stage III lung cancer from returning after Chemo-Radiation
Disease control OngoingThis study tests whether taking osimertinib daily after standard chemoradiation can delay cancer growth in people with stage III EGFR-mutant non-small cell lung cancer that hasn't spread. About 216 adults whose tumors have specific EGFR mutations will receive either osimertinib o…
Matched conditions: NON-SMALL CELL LUNG CANCER STAGE III
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 22, 2026 12:09 UTC
-
New combo therapy aims to stop lung cancer from returning
Disease control OngoingThis study tests whether adding the drug durvalumab to targeted radiation (SBRT) can help keep early-stage non-small cell lung cancer from coming back. It included 13 people with stage I to IIIA disease. The main goal was to see how long they lived without their cancer getting wo…
Matched conditions: NON-SMALL CELL LUNG CANCER STAGE III
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 16, 2026 12:48 UTC
-
Blood test may predict lung cancer outcomes before surgery
Knowledge-focused OngoingThis study is looking at 100 people with stage IIIA lung cancer who are getting treatment before surgery. Researchers want to see if a blood test that looks for tumor DNA (ctDNA) can predict how well patients do. If the tumor DNA disappears after treatment, it might mean a better…
Matched conditions: NON-SMALL CELL LUNG CANCER STAGE III
Sponsor: Fundación GECP • Aim: Knowledge-focused
Last updated Jun 23, 2026 11:55 UTC
-
Gut bacteria may hold key to lung cancer treatment success
Knowledge-focused OngoingThis study looks at whether bacteria from the throat, stool, and lungs can help predict which patients with stage III lung cancer will have their cancer return during immunotherapy (durvalumab) after chemoradiation. Researchers will also check how antibiotics affect treatment sid…
Matched conditions: NON-SMALL CELL LUNG CANCER STAGE III
Sponsor: Leiden University Medical Center • Aim: Knowledge-focused
Last updated Jun 22, 2026 12:08 UTC